Cargando…
Primary Hyperammonaemia: Current Diagnostic and Therapeutic Strategies
Primary hyperammonaemia is a term to describe an elevation of ammonia in blood or plasma due to a defect within the urea cycle, which is the pathway responsible for ammonia detoxification and arginine biosynthesis. Urea cycle disorders (UCDs) are rare diseases caused by genetic defects affecting any...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Sciendo
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8518097/ https://www.ncbi.nlm.nih.gov/pubmed/33179600 http://dx.doi.org/10.34763/jmotherandchild.20202402si.2015.000006 |
_version_ | 1784584151089807360 |
---|---|
author | Häberle, Johannes |
author_facet | Häberle, Johannes |
author_sort | Häberle, Johannes |
collection | PubMed |
description | Primary hyperammonaemia is a term to describe an elevation of ammonia in blood or plasma due to a defect within the urea cycle, which is the pathway responsible for ammonia detoxification and arginine biosynthesis. Urea cycle disorders (UCDs) are rare diseases caused by genetic defects affecting any of the six enzymes or two transporters that are directly involved in the urea cycle function. The clinical situation is variable and largely depends on the time of onset. Newborns who are often affected by hyper-ammonaemic encephalopathy carry a potential risk of severe brain damage, which may lead to death. Outside the neonatal period, symptoms are very unspecific but most often neurological (with wide variability), psychiatric and/or gastrointestinal. Early identification of patients is extremely important to start effective treatment modalities immediately. The acute management includes detoxification of ammonia, which often requires extracorporeal means such as haemodialysis, and the use of intravenous drugs that work as nitrogen scavengers. Long-term management of patients with UCDs consists of a low-protein diet, which needs to be balanced and supplemented to avoid deficiencies of essential amino acids, trace elements or vitamins and the use of nitrogen scavengers. The reader will find here a brief overview describing the most relevant aspects of the clinical management of UCDs in an attempt to raise awareness for this important group of rare diseases. |
format | Online Article Text |
id | pubmed-8518097 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Sciendo |
record_format | MEDLINE/PubMed |
spelling | pubmed-85180972021-11-23 Primary Hyperammonaemia: Current Diagnostic and Therapeutic Strategies Häberle, Johannes J Mother Child Review Paper Primary hyperammonaemia is a term to describe an elevation of ammonia in blood or plasma due to a defect within the urea cycle, which is the pathway responsible for ammonia detoxification and arginine biosynthesis. Urea cycle disorders (UCDs) are rare diseases caused by genetic defects affecting any of the six enzymes or two transporters that are directly involved in the urea cycle function. The clinical situation is variable and largely depends on the time of onset. Newborns who are often affected by hyper-ammonaemic encephalopathy carry a potential risk of severe brain damage, which may lead to death. Outside the neonatal period, symptoms are very unspecific but most often neurological (with wide variability), psychiatric and/or gastrointestinal. Early identification of patients is extremely important to start effective treatment modalities immediately. The acute management includes detoxification of ammonia, which often requires extracorporeal means such as haemodialysis, and the use of intravenous drugs that work as nitrogen scavengers. Long-term management of patients with UCDs consists of a low-protein diet, which needs to be balanced and supplemented to avoid deficiencies of essential amino acids, trace elements or vitamins and the use of nitrogen scavengers. The reader will find here a brief overview describing the most relevant aspects of the clinical management of UCDs in an attempt to raise awareness for this important group of rare diseases. Sciendo 2020-10-02 /pmc/articles/PMC8518097/ /pubmed/33179600 http://dx.doi.org/10.34763/jmotherandchild.20202402si.2015.000006 Text en © 2020 Johannes Häberle, published by Sciendo https://creativecommons.org/licenses/by/4.0/This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. |
spellingShingle | Review Paper Häberle, Johannes Primary Hyperammonaemia: Current Diagnostic and Therapeutic Strategies |
title | Primary Hyperammonaemia: Current Diagnostic and Therapeutic Strategies |
title_full | Primary Hyperammonaemia: Current Diagnostic and Therapeutic Strategies |
title_fullStr | Primary Hyperammonaemia: Current Diagnostic and Therapeutic Strategies |
title_full_unstemmed | Primary Hyperammonaemia: Current Diagnostic and Therapeutic Strategies |
title_short | Primary Hyperammonaemia: Current Diagnostic and Therapeutic Strategies |
title_sort | primary hyperammonaemia: current diagnostic and therapeutic strategies |
topic | Review Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8518097/ https://www.ncbi.nlm.nih.gov/pubmed/33179600 http://dx.doi.org/10.34763/jmotherandchild.20202402si.2015.000006 |
work_keys_str_mv | AT haberlejohannes primaryhyperammonaemiacurrentdiagnosticandtherapeuticstrategies |